AVANIR to Raise $40.0 Million to Fund Zenvia Through Clinical Development and Regulatory Approval
Palo Alto, CA - Nov 26, 2007

Carbylan Announces $20 Million Series B Financing
Aliso Viejo, CA - March 27, 2008

Yaupon Therapeutics closes $14.5 million financing -- Series C financing positions company to advance development of its product portfolio targeting cancer and central nervous system diseases
Radnor, PA - Nov 26, 2007

BioForm Announces Pricing of Initial Public Offering
San Mateo, CA - Nov 07, 2007

Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
Palo Alto, CA ? October 24, 2007 ? Vivo Ventures

APT Pharmaceuticals Closes New $22 Million Funding Round
Burlingame, CA - October 4, 2007

Sagent Pharmaceuticals Inc. Completes $53M Series A Financing
Schaumburg, IL - September 27, 2007

Acura Pharmaceuticals, Inc. secures financing to fund pivotal Phase III clinical trial for lead Aversion® technology product candidate
Palatine, IL - August 20, 2007

Capnia names chairman, CEO
Palo Alto, CA - August 6, 2007

Biodel Inc. Announces Completion of Public Offering
DANBURY, CT - May 17, 2007

Vivo Ventures Announces the Closing of Vivo Ventures Fund VI, a $275M Life Science Venture Fund
Palo Alto, CA - May 7, 2007

TransOral Pharmaceuticals Raises $40 Million in Series D Financing
Pt. Richmond, CA - March 6, 2007

Synapse BioMedical Completes Series C Private Equity Financing
Cleveland, OH, January 16, 2007

InteKrin Therapeutics Secures $23 M Venture Financing
Palo Alto, CA, January 11, 2007

At Vivo Ventures, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors.  Vivo prides itself on its working relationships with its founders who have often continued to work with the firm in other startup ventures.  The majority of Vivo's investments are in U.S. based companies with therapeutic products in clinical development. . . MORE